Diagnostic criteria for Alcoholic cardiomyopathy. by Fei Yan (128878)

“…</p><p><b>Results:</b> Globally, ACM burden showed significant declines from 1990 to 2021, with age-standardized rates decreasing by 22.5-37.1% across prevalence, mortality and disability measures. …”

Questionnaire description. by Cristobal Padilla-Fortunatti (21376807)

Subjects:

EF-24 induces significant transcriptional changes in K-562 cells. by Ajeet P. Singh (22298432)

Subjects:

Demographic and ocular features. by Mingxi Shao (10066570)

“…</p><p>Results</p><p>In the PCG group, H₂O₂ and MDA levels were notably higher than in controls (p < 0.001, <i><i>p</i> </i>= 0.020), while TAS levels were significantly lower (p = 0.043). Adjusting for age and gender, the serum TAS (OR = 0.07, 95% CI 0.01–0.85, <i><i>p</i></i> = 0.037), H₂O₂ (OR = 1.21, 95% CI 1.09–1.35, <i><i>p</i></i> = 0.001) and MDA (OR = 1.17, 95% CI 1.00–1.34, <i><i>p</i></i> = 0.034) were determined to be independent risk/protective factors for PCG. …”

Machine learning model to diagnose PCG. by Mingxi Shao (10066570)

“…</p><p>Results</p><p>In the PCG group, H₂O₂ and MDA levels were notably higher than in controls (p < 0.001, <i><i>p</i> </i>= 0.020), while TAS levels were significantly lower (p = 0.043). Adjusting for age and gender, the serum TAS (OR = 0.07, 95% CI 0.01–0.85, <i><i>p</i></i> = 0.037), H₂O₂ (OR = 1.21, 95% CI 1.09–1.35, <i><i>p</i></i> = 0.001) and MDA (OR = 1.17, 95% CI 1.00–1.34, <i><i>p</i></i> = 0.034) were determined to be independent risk/protective factors for PCG. …”

ROC curves of TAS + SOD + MDA to diagnose PCG. by Mingxi Shao (10066570)

“…</p><p>Results</p><p>In the PCG group, H₂O₂ and MDA levels were notably higher than in controls (p < 0.001, <i><i>p</i> </i>= 0.020), while TAS levels were significantly lower (p = 0.043). Adjusting for age and gender, the serum TAS (OR = 0.07, 95% CI 0.01–0.85, <i><i>p</i></i> = 0.037), H₂O₂ (OR = 1.21, 95% CI 1.09–1.35, <i><i>p</i></i> = 0.001) and MDA (OR = 1.17, 95% CI 1.00–1.34, <i><i>p</i></i> = 0.034) were determined to be independent risk/protective factors for PCG. …”

Lymphocyte proliferation assay following combination therapy with NDV. by Hedieh Zargaran (21410233)

Tumor volume measurements. by Hedieh Zargaran (21410233)

Trends over 10 years (2011–2021) in clinical characteristics of children with severe acute malnutrition admitted at Moyo NRU. by Mphatso Nancy Chisala (20477275)

Trends over 10 years in children with severe acute malnutrition admitted at Moyo NRU. by Mphatso Nancy Chisala (20477275)

IL-10 levels in tumor lysates post-treatment. by Hedieh Zargaran (21410233)

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of newly emerged summer worker bees inoculated with 1 × 10⁷ CFU/bee <i>M. plutonius</i> 2019BC1 and/or treated... by Midhun Sebastian Jose (19336846)

CTL response following combination therapy with NDV. by Hedieh Zargaran (21410233)

<b>The moderating effect of financial literacy on risk preferences and time preferences</b> by Calvin Mudzingiri (22188109)

“…Additionally, the study concluded that time preferences significantly moderate financial literacy. An increase in financial literacy is associated with a decrease in time preferences, indicating that as financial literacy rises, subjects become more patient. …”

电针预处理通过心肌缺血损伤 棕色脂肪组织和 BMP3b/Smad1/5 通路小鼠 by Danying Qian (21730250)

Subjects: “…electroacupuncture significantly decreased…”

Box plots showing the taxa that were significantly different between thin and normal cows. by Bhuripit Saraphol (20855573)

Subjects:

Production and metabolic processes for dimethylarginine. by Afeefa Zainab (20141773)

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”